Mitsubishi Tanabe Pharma, Astrazeneca partner on diabetic nephropathy research
The three-year research is aimed at leveraging complementary strengths, expertise and assets to certify and progress new research targets and molecules into clinical development. Spanning from target selection
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.